Irbesartan/Hydrochlorothiazide Mylan

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide Mylan, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, primarily in adult patients, by relaxing blood vessels and reducing fluid volume.

GNH USA supplies Irbesartan/Hydrochlorothiazide Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk. Essential hypertension: provides combined vasodilation and diuresis for better blood‑pressure control. Fluid overload associated with hypertension: promotes sodium and water excretion to decrease blood volume.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild hypotension

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Allergic reactions such as rash, angioedema, or Stevens‑Johnson syndrome - Significant drop in blood pressure leading to syncope - Pancreatitis (rare) - Severe hyperuricemia or gout flare

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly: adjust therapy if target levels are not achieved. - Check serum electrolytes (especially potassium and sodium): correct imbalances promptly. - Assess renal function: avoid use in severe renal impairment. - Use caution in patients with diabetes: monitor glucose as diuretics may affect glycemic control. - Avoid in patients with severe hepatic disease: drug metabolism may be altered. - Store at room temperature: keep in the original container, protect from moisture and direct light.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia. - Lithium: thiazide component can raise lithium levels, leading to toxicity. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure lowering, monitor for hypotension. - Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustments. - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): can increase irbesartan plasma concentrations. - Additional thiazide diuretics: may cause excessive diuresis and electrolyte loss.